Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 1.020
-0.014 (-1.35%)
Aug 13, 2026, 5:29 PM CET
Diamyd Medical AB Market Cap
Diamyd Medical AB has a market cap or net worth of 158.08 million as of August 13, 2026. Its market cap has decreased by -89.66% in one year.
Market Cap
158.08M
Enterprise Value
-188.02M
Revenue
432.00K
Ranking
n/a
PE Ratio
n/a
Stock Price
1.02
ChartMarket Cap Chart
Since May 20, 2013, Diamyd Medical AB's market cap has increased from 132.51M to 158.08M, an increase of 19.30%. That is a compound annual growth rate of 1.34%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 13, 2026 | 158.08M | -89.79% |
| Dec 30, 2025 | 1.55B | -9.52% |
| Dec 30, 2024 | 1.71B | 182.47% |
| Dec 29, 2023 | 605.80M | -41.10% |
| Dec 30, 2022 | 1.03B | -9.66% |
| Dec 30, 2021 | 1.14B | -46.65% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Xbrane Biopharma AB | 209.14M |
| Alzinova AB | 206.69M |
| Initiator Pharma | 177.29M |
| Abera Bioscience AB | 173.42M |
| Elicera Therapeutics AB | 168.84M |
| Biovica International AB | 161.13M |
| Xintela AB | 160.63M |
| Nanologica AB | 148.93M |